Acute chest pain/tightness
Conditions
Interventions
Kuanxiong Aerosol Group:Kuanxiong Aerosol: 3 sprays. May repeat x2 at 5-minute intervals if unrelieved. If pain persists after 3 doses (total 9 sprays), follow chest pain protocol.
Nitroglycerin Tablets Group:Nitroglycerin: 1 tablet sublingually. If pain is unrelieved after 5 minutes, repeat every 5 minutes for a maximum of 3 doses. If no relief after 3 doses, follow chest pain
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
25 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Patients presenting to the emergency department with symptoms such as "chest tightness" or "chest pain". 2.Patients still experiencing significant pain (NRS >= 4) at the time of presentation, with pain duration of more than 3 minutes. 3.Aged between 25 and 80 years, regardless of gender. 4.Patients who are conscious and able to clearly describe their symptoms of chest tightness and pain. 5.Voluntary participation in this clinical trial, with understanding and signing of the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients with unstable vital signs requiring emergency resuscitation. 2.Patients with traumatic chest pain. 3.Significant relief of symptoms such as "chest tightness" or "chest pain" experienced by the patient prior to the emergency department visit. 4.Patients with unstable blood pressure, or systolic blood pressure < 90 mmHg / diastolic blood pressure < 60 mmHg. 5.Known or suspected allergy to any component of Kuanxiong Aerosol or nitroglycerin; or allergy to alcohol. 6.Use of Kuanxiong Aerosol or similar medications (e.g., medium- to long-acting nitrates, Compound Danshen Dripping Pills, Shexiang Baoxin Pills, etc.) within 72 hours prior to the emergency visit, or use of nitroglycerin within 24 hours prior to the emergency visit. 7.Patients in special physiological periods, such as lactation or pregnancy. 8.Patients with psychiatric disorders or impaired consciousness. 9.Patients with angle-closure glaucoma, cardiogenic shock, severe ventricular arrhythmia, or complete atrioventricular block. 10.Patients with other severe concomitant cardiopulmonary diseases, such as obstructive cardiomyopathy, cardiac tamponade, pulmonary embolism, etc. 11.Patients with severe hepatic or renal dysfunction, advanced malignant tumors, severe hematopoietic system diseases, or other serious illnesses. 12.Participation in another clinical study within 30 days prior to enrollment, or previous randomization in this study. 13.Patients deemed by the investigator as unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chest Pain Relief Rate within 10 Minutes of Treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Chest Pain Relief Rate at 5 and 30 Minutes Post-dose;Reduction in NRS Score After First Dose;Quality of Life Scale(ED-5D); | — |
Countries
China
Contacts
Public ContactXingang Wang
Peking University First Hospital
Outcome results
None listed